Clinical Study to Evaluate the Pharmacokinetics, Safety, Tolerability and Pharmacodynamic Effects of a Single Oral 10 mg BAY1101042 Tablet Dose in Men and Woman With Renal Impairment and in Healthy Subjects

Inclusion Criteria: * Ability to understand and follow study-related instructions and ability to participate in the study for the entire period. * Age: 18 to 79 years (inclusive) at the screening visit. * Body mass index (BMI): 18 to 34 kg/m² (both inclusive). * Male or female subject. * Only women without childbearing potential will be included in the study (e.g. postmenopausal for at least one year, women with bilateral ovariectomy and women with hysterectomy). Subjects with renal impairment: * eGFR \<90 mL/min/1.73 m\*2 determined from serum creatinine 2-10 days prior to dosing. * Stable renal disease, i.e. a serum creatinine value determined at least 3 months before the pre-study visit (e.g. during routine diagnostics) should not vary by more than 20% from the serum creatinine value determined at the pre-study visit. Healthy subjects: \- eGFR ≥90 mL/min/1.73 m\*2 determined from serum creatinine 2-10 days prior to dosing. Exclusion Criteria: * Pregnant or lactating women. * Medical disorder, condition or history of such that would impair the subject's ability to participate or complete this study in the opinion of the investigator.